Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NKG2D-CAR-NK92
- Development stage
- Phase 1
- Lead developer
- Celyad Oncology
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
NKG2D-CAR-NK92 is an engineered natural killer cell therapy based on the NK-92 cell line. These cells are modified to express a chimeric antigen receptor (CAR) consisting of the extracellular domain of NKG2D fused to transmembrane and intracellular domains of CD3ζ. The therapy targets stress-induced ligands (NKG2DL) expressed by many tumor cells, enabling specific recognition and killing of cancer cells. Some versions also co-express an IL-15 superagonist (RD-IL15) to enhance NK cell growth and activity without requiring cross-presentation of IL-15 by IL-15Rα.
- Other names
- NKAR-NK-92NKAR-NK92NKAR-NK 92NKG2D-CAR NK-92NKG-2D-CAR NK-92NKG 2D-CAR NK-92
02
Targets
MICB (Major histocompatibility complex class i-related protein B)
Beyond the preview
Go deeper on NKG2D-CAR-NK92.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NKG2D-CAR-NK92.